Pure Global
NCT06399666

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation Recurrence Following Electrical Cardioversion

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation
Vrinnevi Hospital·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atrial Fibrillation,Inflammation,Genetic Predisposition to Disease
Drug/Device/Intervention
Blood sampling
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Vrinnevi Hospital
Location
Jönköping,Norrköping, Sweden
Timeline & enrollment
Phase
N/A
Start date
Oct 30, 2023
End date
Feb 28, 2026
Enrollment
205 participants
Primary outcome

Recurrence in atrial fibrillation

Summary

Because of the high recurrence rates following electrical cardioversion and high morbidity in
 AF patients there is a need to explore prediction models for AF recurrence following ECV.
 Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while
 other inflammatory indexes and gene scores might hold greater value.
 
 This prospective cohort study is planning to include 205 patients with persistent atrial
 fibrillation, planned for electrical cardioversion, and 18 years at two medium-sized
 hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at
 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at
 follow-up or upon patient request and diagnosed with 12-lead ECG.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterOther ill-defined heart diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06399666
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06399666 through Pure Global AI's free database. This phase not specified trial is sponsored by Vrinnevi Hospital and is currently Recruiting. The study focuses on Atrial Fibrillation,Inflammation,Genetic Predisposition to Disease. Target enrollment is 205 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.